Compare Bristol-Myers Squibb Co (BMY) vs Invesco DB Agriculture Fund (DBA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Invesco DB Agriculture Fund — how do they compare? Bristol-Myers Squibb Co trades at $63.41 (market cap $132.45B), while Invesco DB Agriculture Fund trades at $27.6. The key difference: Bristol-Myers Squibb Co pays a 3.89% dividend while Invesco DB Agriculture Fund pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, Invesco DB Agriculture Fund nearer its low. Which is the better fit depends on your goals.
| BMY | DBA | |
|---|---|---|
Market Cap | $132.45B | — |
Sector | Health | — |
52-Week High | $65.89 | $28.73 |
52-Week Low | $42.60 | $25.44 |
Enterprise Value | $166.44B | — |
Dividend Yield | 3.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
DBA, the Invesco DB Agriculture Fund ETF, trades at $27.62, up 0.69% today, and has shown strong performance with a 5% gain over the past month, outperforming the S&P 500. The technical outlook is bullish based on moving averages, while oscillators are neutral. Recent news highlights agricultural commodity strength, with DBA consolidating near highs amid a bullish trend since 2020, supported by a 3.25% yield and diversified futures exposure.
The outlook for DBA remains positive due to favorable agricultural market conditions and geopolitical factors driving commodity prices. Key risks include sector volatility and management fees. Analyst sentiment is constructive, viewing the ETF as a play on rising agricultural demand, though investors should monitor commodity price fluctuations and global supply chain disruptions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Invesco DB Agriculture Fund
The index, which is comprised of one or more underlying commodities ("index commodities"), is intended to reflect the agricultural sector. The fund pursues its investment objective by investing in a portfolio of exchange-traded futures.
Read more on DBA →
